Contact Information

37 Westminster Buildings, Theatre Square,
Nottingham, NG1 6LG

We Are Available 24/ 7. Call Now.
Roivant in Talks to Sell Stomach Drug to Roche in Deal Valued at More Than $7 Billion
Business

Roivant in Talks to Sell Stomach Drug to Roche in Deal Valued at More Than $7 Billion

Roivant, started by presidential candidate Vivek Ramaswamy, could seal a deal in coming days. Source link

Roivant in Talks to Sell Stomach Drug to Roche in Deal Valued at More Than $7 Billion
Finances

Roivant in Talks to Sell Stomach Drug to Roche in Deal Valued at More Than $7 Billion

Roivant, started by presidential candidate Vivek Ramaswamy, could seal a deal in coming days Source link

Illumina Fined More Than $400 Million in Europe for Closing Grail Deal Early
Business

Illumina Fined More Than $400 Million in Europe for Closing Grail Deal Early

The European Union’s antitrust watchdog fined the company with the maximum allowable amount for wrapping up its acquisition of the cancer-test developer while the agency

FDA Approval Isn't Always a Happy Day for Biotech Investors
Business

FDA's OK Isn't Always a Happy Day for Biotech Investors

In recent weeks, three closely watched FDA decisions came in positive for the companies—followed by their stocks going negative. Source link

FDA Approval Isn't Always a Happy Day for Biotech Investors
Finances

FDA Approval Isn't Always a Happy Day for Biotech Investors

In recent weeks, three closely watched FDA decisions came in positive for the companies—followed by their stocks going negative. Source link

Obesity Drugs Won't Starve These Other Potential Blockbusters
Finances

Obesity Drugs Won't Starve These Other Potential Blockbusters

Stocks of developers of fatty liver disease treatments had been on a tear until results from Eli Lilly’s medication were published last week. Source link

Moderna, Merck Show Progress Toward Cancer Vaccines
Business

Moderna, Merck Show Progress Toward Cancer Vaccines

An mRNA shot helped prevent relapse in high-risk melanoma patients. Source link

Merck in Late-Stage Talks to Acquire Prometheus Biosciences
Finances

Merck in Late-Stage Talks to Acquire Prometheus Biosciences

Merck & Co. is in late-stage talks to acquire Prometheus Biosciences Inc., according to people familiar with the matter, a move that could give the